Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Urogen Pharma (0XOD) Share Price & Analysis

1 Followers

0XOD Stock Chart & Stats

$25.99$0.67(2.65%)
At close: 4:30 PM GMT
$30$40$50Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$25.63 - $26.35
52-Week Range
$16.19 - $51.11
Previous Close
$25.32
Volume
N/A
Average Volume (3M)
743
Market Cap
$1.24B
Enterprise Value
$2.16B
Total Cash (Recent Filing)
$90.55M
Total Debt (Recent Filing)
$196.28M
Price to Earnings (P/E)
―
Beta
1.00
Next Earnings
Mar 18, 2027 (Est.)
EPS Estimate
0.39
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Zosturi Commercial Growth And Adoption

Rapid Zosturi revenue growth, increasing repeat use, and expanding physician adoption indicate improving commercial traction for the company’s lead growth product. Continued penetration across community practices could support durable revenue expansion as more prescribers gain experience with the treatment.

Strong Product Economics

Strong revenue growth combined with an exceptionally high gross margin demonstrates attractive product-level economics and meaningful operating leverage potential. If commercial expansion continues, the company has a credible path to convert increasing sales into improving profitability as fixed investments are absorbed.

Advancing Pipeline And Regulatory Support

FDA acceptance of UGN-103 for review materially advances a potential second commercial opportunity and reduces development uncertainty relative to earlier pipeline stages. Regulatory progress, supported by Phase 3 results, could broaden the product base and strengthen long-term growth beyond Zosturi.

Bears Say

Persistent Cash Burn

Substantial ongoing cash outflows mean UroGen has not yet converted commercial revenue into internally generated funding. Continued investment in launches and clinical programs may require external capital if the anticipated profitability improvement is delayed, limiting financial flexibility over the medium term.

Negative Equity And Leverage

Negative equity alongside significant debt leaves the company with a thin capitalization cushion and reduces balance-sheet flexibility. This structure can constrain funding choices, increase sensitivity to execution setbacks, and make continued progress toward profitability more important for maintaining financial stability.

Jelmyto Competitive And Market Pressure

Jelmyto faces a structurally constrained eligible-patient pool while competing studies target the same disease area and may draw from heavy users. Persistent trial-related pressure could limit patient starts and revenue durability, making the company increasingly dependent on successful Zosturi growth.

Urogen Pharma News

0XOD FAQ

What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest share price was $16.19 and its highest was $51.11 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.24B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s next earnings report is estimated for Mar 18, 2027 (not yet confirmed), which is in 125 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Nov 04, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of $0.106 by -$0.136.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is 0.39.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 49,047,825 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.03 in its last earnings report, missing expectations of $0.106. Following the earnings report the stock price went down -15.568%.
Which hedge fund is a major shareholder of Urogen Pharma?
Hedge funds hold Urogen Pharma shares: the largest hedge-fund position in Urogen Pharma is 274,144,273 shares, and hedge funds increased their holdings by 28.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology